191 related articles for article (PubMed ID: 36785760)
1. Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Montazeri K; Pattanayak V; Sullivan RJ
Drug Des Devel Ther; 2023; 17():333-339. PubMed ID: 36785760
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report.
Reiter S; Schroeder C; Broche J; Sinnberg T; Bonzheim I; Süsskind D; Flatz L; Forschner A
Front Oncol; 2023; 13():1167791. PubMed ID: 37207136
[TBL] [Abstract][Full Text] [Related]
3. Gp-100 as a Novel Therapeutic Target in Uveal Melanoma.
Martinez-Perez D; Viñal D; Solares I; Espinosa E; Feliu J
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885078
[TBL] [Abstract][Full Text] [Related]
4. Tebentafusp for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
Chen LN; Carvajal RD
Expert Rev Anticancer Ther; 2022 Oct; 22(10):1017-1027. PubMed ID: 36102132
[TBL] [Abstract][Full Text] [Related]
5. Tebentafusp: First Approval.
Dhillon S
Drugs; 2022 Apr; 82(6):703-710. PubMed ID: 35364798
[TBL] [Abstract][Full Text] [Related]
6. Tebentafusp in advanced uveal melanoma: proof of principle for the efficacy of T-cell receptor therapeutics and bispecifics in solid tumors.
Liu AW; Wei AZ; Maniar AB; Carvajal RD
Expert Opin Biol Ther; 2022 Aug; 22(8):997-1004. PubMed ID: 35060440
[TBL] [Abstract][Full Text] [Related]
7. Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.
Wang Z; Xie Y; Wang JQ; Cheng Y; Fleishman J; Chen ZS; Chen Y
Drugs Today (Barc); 2023 Mar; 59(3):179-193. PubMed ID: 36847626
[TBL] [Abstract][Full Text] [Related]
8. Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma.
Damato BE; Dukes J; Goodall H; Carvajal RD
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31336704
[TBL] [Abstract][Full Text] [Related]
9. Tebentafusp as a Promising Drug for the Treatment of Uveal Melanoma.
Al Balushi K; Al Hadhrami A; Balushi HA; Al Lawati A; Das S
Curr Drug Targets; 2024; 25(3):149-157. PubMed ID: 38115619
[TBL] [Abstract][Full Text] [Related]
10. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.
Nathan P; Hassel JC; Rutkowski P; Baurain JF; Butler MO; Schlaak M; Sullivan RJ; Ochsenreither S; Dummer R; Kirkwood JM; Joshua AM; Sacco JJ; Shoushtari AN; Orloff M; Piulats JM; Milhem M; Salama AKS; Curti B; Demidov L; Gastaud L; Mauch C; Yushak M; Carvajal RD; Hamid O; Abdullah SE; Holland C; Goodall H; Piperno-Neumann S;
N Engl J Med; 2021 Sep; 385(13):1196-1206. PubMed ID: 34551229
[TBL] [Abstract][Full Text] [Related]
11. Successful application of chemosaturation with percutaneous hepatic perfusion in metastatic uveal melanoma patient progressing after systemic treatment options: a case report.
Gunenc D; Ozluk AA; Yıldırım UM; Ascierto PA; Karaca B
Front Oncol; 2024; 14():1355971. PubMed ID: 38660135
[TBL] [Abstract][Full Text] [Related]
12. Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.
Middleton MR; McAlpine C; Woodcock VK; Corrie P; Infante JR; Steven NM; Evans TRJ; Anthoney A; Shoushtari AN; Hamid O; Gupta A; Vardeu A; Leach E; Naidoo R; Stanhope S; Lewis S; Hurst J; O'Kelly I; Sznol M
Clin Cancer Res; 2020 Nov; 26(22):5869-5878. PubMed ID: 32816891
[TBL] [Abstract][Full Text] [Related]
13. Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond.
Gerard C; Shum B; Nathan P; Turajlic S
Immunooncol Technol; 2023 Sep; 19():100386. PubMed ID: 37483658
[TBL] [Abstract][Full Text] [Related]
14. Tebentafusp: a first-in-class treatment for metastatic uveal melanoma.
Howlett S; Carter TJ; Shaw HM; Nathan PD
Ther Adv Med Oncol; 2023; 15():17588359231160140. PubMed ID: 36970111
[TBL] [Abstract][Full Text] [Related]
15. Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma.
Hua G; Carlson D; Starr JR
J Adv Pract Oncol; 2022 Sep; 13(7):717-723. PubMed ID: 36199496
[TBL] [Abstract][Full Text] [Related]
16. Tumor lysis syndrome induced by tebentafusp.
Ruf T; Leonhardt A; Anz D; Kunz WG; Röhrle N; Foerster P; Tomsitz D; French LE; Seegräber M; Heinzerling L
Immunotherapy; 2023 Nov; 15(16):1363-1368. PubMed ID: 37661909
[TBL] [Abstract][Full Text] [Related]
17. Review of bi-specific therapies in uveal melanoma.
Orloff M; Seedor R; Sato T
Cancer Gene Ther; 2022 Dec; 29(12):1814-1818. PubMed ID: 35236927
[TBL] [Abstract][Full Text] [Related]
18. Tebentafusp for the treatment of metastatic uveal melanoma.
Schank TE; Hassel JC
Future Oncol; 2022 Apr; 18(11):1303-1311. PubMed ID: 35172589
[TBL] [Abstract][Full Text] [Related]
19. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.
Hassel JC; Piperno-Neumann S; Rutkowski P; Baurain JF; Schlaak M; Butler MO; Sullivan RJ; Dummer R; Kirkwood JM; Orloff M; Sacco JJ; Ochsenreither S; Joshua AM; Gastaud L; Curti B; Piulats JM; Salama AKS; Shoushtari AN; Demidov L; Milhem M; Chmielowski B; Kim KB; Carvajal RD; Hamid O; Collins L; Ranade K; Holland C; Pfeiffer C; Nathan P
N Engl J Med; 2023 Dec; 389(24):2256-2266. PubMed ID: 37870955
[TBL] [Abstract][Full Text] [Related]
20. Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma.
Roshardt Prieto NM; Turko P; Zellweger C; Nguyen-Kim TDL; Staeger R; Bellini E; Levesque MP; Dummer R; Ramelyte E
Melanoma Res; 2024 Apr; 34(2):166-174. PubMed ID: 38126339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
